Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Pathology, Beijing Boren Hospital, Beijing, China.
Front Immunol. 2024 Mar 27;15:1371534. doi: 10.3389/fimmu.2024.1371534. eCollection 2024.
Nodal T-follicular helper cell lymphomas (nTFHLs) represent a new family of peripheral T-cell lymphomas (PTCLs), and comparative studies of their constituents are rare.
This study retrospectively enrolled 10 patients with nTFHL-F and 30 patients with nTFHL-NOS diagnosed between December 2017 and October 2023 at six large comprehensive tertiary hospitals; 188 patients with nTFHL-AI were diagnosed during the same period at the First Affiliated Hospital of Zhengzhou University for comparison.
Compared with nTFHL-AI, nTFHL-NOS patients exhibited better clinical manifestations, lower TFH expression levels, and a lower Ki-67 index. However, no differences in clinicopathological features were observed between nTFHL-F and nTFHL-AI patients as well as nTFHL-NOS patients. According to the survival analysis, the median OS for patients with nTFHL-NOS, nTFHL-AI, and nTFHL-F were 14.2 months, 10 months, and 5 months, respectively, whereas the median TTP were 14 months, 5 months, and 3 months, respectively. Statistical analysis revealed differences in TTP among the three subtypes(=0.0173). Among the population of patients receiving CHOP-like induction therapy, there were significant differences in the OS and TTP among the nTFHL-NOS, nTFHL-AI, and nTFHL-F patients (=0.0134, =0.0205). Both the GDPT and C-PET regimens significantly improved the ORR, OS, and PFS in nTFHL patients.
There are significant differences in the clinical manifestations, pathology, and survival outcomes among the three subtypes of nTFHLs. However, further research with a larger sample size, and involving clinical pathology and molecular genetics is needed to determine the distinctive biological characteristics of these tumors.
结内滤泡辅助性 T 细胞淋巴瘤(nTFHL)是外周 T 细胞淋巴瘤(PTCL)的一个新家族,对其构成成分的比较研究较为罕见。
本研究回顾性纳入了 2017 年 12 月至 2023 年 10 月期间在六家大型综合三级医院诊断的 10 例 nTFHL-F 和 30 例 nTFHL-NOS 患者;同期在郑州大学第一附属医院诊断的 188 例 nTFHL-AI 患者作为对照。
与 nTFHL-AI 相比,nTFHL-NOS 患者的临床表现更好,TFH 表达水平更低,Ki-67 指数更低。然而,nTFHL-F 与 nTFHL-AI 患者以及 nTFHL-NOS 患者之间在临床病理特征方面没有差异。根据生存分析,nTFHL-NOS、nTFHL-AI 和 nTFHL-F 患者的中位 OS 分别为 14.2 个月、10 个月和 5 个月,中位 TTP 分别为 14 个月、5 个月和 3 个月。统计分析显示,这三种亚型的 TTP 有差异(=0.0173)。在接受 CHOP 样诱导治疗的患者中,nTFHL-NOS、nTFHL-AI 和 nTFHL-F 患者的 OS 和 TTP 存在显著差异(=0.0134,=0.0205)。GDPT 和 C-PET 方案均显著提高了 nTFHL 患者的 ORR、OS 和 PFS。
nTFHL 三种亚型在临床表现、病理学和生存结果方面存在显著差异。然而,需要进一步的研究,包括更大的样本量、临床病理学和分子遗传学,以确定这些肿瘤的独特生物学特征。